Literature DB >> 8460928

Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model.

L B Rice1, L L Carias, D M Shlaes.   

Abstract

We examined the efficacy of ampicillin-sulbactam (2:1) and cefoxitin in the treatment of infections caused by Escherichia coli strains exhibiting increasing levels of beta-lactamase-mediated resistance to ampicillin-sulbactam in the rat intra-abdominal abscess model. Cefoxitin was superior to ampicillin-sulbactam in the treatment of infections caused by all strains. Treatment with ampicillin-sulbactam resulted in a statistically significant decrease in CFU per gram of abscess in comparison with treatment with ampicillin alone for both the moderately resistant and the resistant strains, with an inverse correlation between the MIC and the absolute decrease in CFU per gram of abscess.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8460928      PMCID： PMC187716          DOI： 10.1128/AAC.37.3.610

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.

Authors:  L B Rice; J D Yao; K Klimm; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

2.  Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins.

Authors:  R Labia; A Morand; K Tiwari; J Sirot; D Sirot; A Petit
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

3.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

5.  Amoxycillin/clavulanate resistant Escherichia coli.

Authors:  H Williams; A King; K Shannon; I Phillips
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

6.  Resistance to beta-lactam/clavulanate.

Authors:  J L Martinez; E Cercenado; M Rodriguez-Creixems; M F Vincente-Perez; A Delgado-Iribarren; F Baquero
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

7.  Randomized, prospective comparison of cefoxitin and gentamicin-clindamycin in the treatment of acute colonic diverticulitis.

Authors:  J M Kellum; H J Sugerman; G F Coppa; L R Way; R Fine; B Herz; E L Speck; D Jackson; R J Duma
Journal:  Clin Ther       Date:  1992 May-Jun       Impact factor: 3.393

8.  Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.

Authors:  L Guerra-Romero; S L Kennedy; M A Fournier; J H Tureen; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  Effects of CO2 and pH on inhibition of TEM-1 and other beta-lactamases by penicillanic acid sulfones.

Authors:  D M Livermore; J E Corkill
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Comparison of polyacrylamide and agarose gel thin-layer isoelectric focusing for the characterization of beta-lactamases.

Authors:  C Vecoli; F E Prevost; J J Ververis; A A Medeiros; G P O'Leary
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191
View more
  3 in total

1.  Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.

Authors:  K C Lamp; M K Vickers
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

2.  In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.

Authors:  L B Rice; L L Carias; D M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms.

Authors:  L B Rice; L L Carias; L Etter; D M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.